Jedd D. Wolchok

Jedd D. Wolchok, MD, PhD, FASCO, FAACR, is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and Professor of Medicine at Weill Cornell Medical College. Appointed in September 2022, he transitioned from Memorial Sloan Kettering Cancer Center where he served for over 25 years as Chief of the Immuno-Oncology Service and Lloyd J. Old Chair in Clinical Investigation. Dr. Wolchok is the global pioneer of combination immunotherapy for cancer. In 2013, he led the first-in-human Phase 1 trial combining ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) for advanced melanoma (NEJM, PMID 23724867), establishing the feasibility and clinical activity of dual checkpoint blockade. He subsequently designed and led CheckMate-067, the landmark Phase 3 trial that revolutionized melanoma treatment. CheckMate-067's unprecedented 10-year follow-up data, published in January 2025 (NEJM, PMID 39282897), demonstrated that 43% of patients receiving nivolumab plus ipilimumab survived 10 years—compared to 37% with nivolumab alone and 19% with ipilimumab alone. Remarkably, just 15 years ago, this patient population had a median survival of less than one year. These results established immunotherapy as the standard treatment for advanced melanoma and led to FDA approval of the combination in 2015. Dr. Wolchok's clinical research directly enabled the regulatory approvals of ipilimumab and the nivolumab-ipilimumab combination, fundamentally transforming cancer care. Elected to the National Academy of Medicine and recognized as ASCO Fellow and AACR Fellow, he received the 2026 IO360° Lifetime Achievement Award, the 2022 David A. Karnofsky Memorial Award (ASCO's highest honor), and multiple other prestigious awards including the AACR Burchenal Award and Giants of Cancer Care Award. With 241,856 citations and serving as Treasurer of the Society for Immunotherapy of Cancer, Dr. Wolchok continues advancing combination immunotherapy strategies and leading Weill Cornell's pursuit of NCI Cancer Center designation.

Jedd D. Wolchok医学博士、哲学博士现任Weill Cornell Medicine的Sandra and Edward Meyer癌症中心Meyer主任和Weill Cornell医学院医学教授。2022年9月就任该职位前,他在纪念斯隆-凯特琳癌症中心工作25年以上,担任免疫肿瘤学服务主任和Lloyd J. Old临床研究讲席教授。 Wolchok博士是癌症联合免疫治疗的全球先驱。2013年,他领导了首个在人体中联合使用ipilimumab(抗CTLA-4)和nivolumab(抗PD-1)治疗晚期黑色素瘤的Phase 1试验(NEJM, PMID 23724867),证明了双检查点阻断的可行性和临床活性。随后他设计并领导了CheckMate-067这一革命性的里程碑Phase 3试验。 CheckMate-067前所未有的10年随访数据于2025年1月发表(NEJM, PMID 39282897),显示接受nivolumab联合ipilimumab治疗的患者10年总生存率达43%——相比之下nivolumab单药为37%、ipilimumab单药为19%。值得注意的是,仅在15年前,这类患者的中位生存期不到1年。这些结果确立了免疫治疗作为晚期黑色素瘤标准治疗的地位,并促成联合疗法于2015年获FDA批准。 Wolchok博士的临床研究直接促成了ipilimumab和nivolumab-ipilimumab联合疗法的监管批准,从根本上改变了癌症治疗。他当选为美国国家医学院院士、ASCO会士和AACR会士,获2026年IO360°终身成就奖、2022年David A. Karnofsky纪念奖(ASCO最高荣誉)以及AACR Burchenal奖、Giants of Cancer Care奖等多项殊荣。 Wolchok博士的研究获241,856次引用,现任国际免疫治疗学会财务主管,继续推进联合免疫治疗策略并领导Weill Cornell追求NCI癌症中心指定。